Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Ildiko LingvayKirstine Brown-FrandsenHelen M ColhounJohn DeanfieldScott S EmersonSille EsbjergSøren Hardt-LindbergG Kees HovinghSteven E KahnRobert F KushnerA Michael LincoffSteven P MarsoTea Monk FriesJorge PlutzkyDonna H Ryannull nullPublished in: Obesity (Silver Spring, Md.) (2022)
The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.